Cabaletta Bio
CABA

$7.19

6.52%

Market Cap: 347M

About: Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.

Employees: 120

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 11 analysts

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

200% more first-time investments, than exits

New positions opened: 45 | Existing positions closed: 15

24% more funds holding

Funds holding: 127 [Q4 2023] → 157 (+30) [Q1 2024]

2% less repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 47

7.47% less ownership

Funds ownership: 113.28% [Q4 2023] → 105.81% (-7.47%) [Q1 2024]

21% less capital invested

Capital invested by funds: $1.1B [Q4 2023] → $871M (-$231M) [Q1 2024]

43% less call options, than puts

Call options by funds: $8.87M | Put options by funds: $15.6M

60% less funds holding in top 10

Funds holding in top 10: 5 [Q4 2023] → 2 (-3) [Q1 2024]

See Fund Rankings

Research analyst outlook

11 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$30

317%

upside

Avg. target

$37

410%

upside

High target

$50

595%

upside

11 analyst ratings

11 positive

100%

0 neutral

0%

0 negative

0%

Cantor Fitzgerald Josh Schimmer	595%upside $50	Overweight Reiterated	21 Jun 2024
Stifel Ben Burnett	345%upside $32	Buy Maintained	17 Jun 2024
HC Wainwright & Co. Douglas Tsao	317%upside $30	Buy Reiterated	14 Jun 2024
HC Wainwright & Co. Douglas Tsao	317%upside $30	Buy Reiterated	24 May 2024
HC Wainwright & Co. Douglas Tsao	317%upside $30	Buy Reiterated	16 May 2024

See Analyst Rankings

Financial journalist opinion

Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum

PHILADELPHIA, July 02, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief Executive Officer, will participate in a fireside chat at the Stifel 2024 Virtual Cell Therapy Forum on Tuesday, July 9, 2024, at 1:00 p.m. ET.

Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum

Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment

Cabaletta Bio focuses on autoimmune diseases with a potential best-in-class cell therapy, CABA-201, showing promise in early studies. It's stock price rose >$25 due to positive data produced by a drug with the same MoA as CABA-201, showing remarkable results with many patients experiencing full recoveries. Cabaletta stock has been sinking in 2024 however due to slow progress, manufacturing concerns, and disappointing recent data release.

Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment

Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201

– No CRS, ICANS, infections or serious adverse events observed in either of the first two patients through data cut-off of May 28, 2024 –

Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201

Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update

– No CRS or ICANS of any grade observed during the 28-day DLT observation window for either of the first patients dosed with CABA-201 in the RESET-Myositis™ and RESET-SLE™ trials –

Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update

Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

PHILADELPHIA, May 13, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on Monday, May 20, 2024 at 9:30 a.m. ET in New York, NY.

Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

– First patient dosed with CABA-201 in the RESET™ (REstoring SElf-Tolerance) clinical trial program – – Initial clinical data from each of the first patients in the RESET-Myositis™ and RESET-SLE™ trials anticipated in 1H24; longer term follow-up on these and additional patients to be reported in 2H24 – – RESET-SSc™ (systemic sclerosis) and RESET-MG™ trials initial clinical data anticipated to be reported in 2H24 – – Rare Pediatric Disease designation granted by FDA for CABA-201 in juvenile dermatomyositis – – Cash runway into 1H26 with cash, cash equivalents and short-term investments of $241.2 million as of December 31, 2023 – PHILADELPHIA, March 21, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update. “Throughout the past year, we set the foundation to enable an efficient development strategy for CABA-201 across a broad range of autoimmune diseases.

Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Cabaletta Bio to Participate in Upcoming Investor Conferences in March

PHILADELPHIA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the Company will participate in two upcoming investor conferences in March:

Cabaletta Bio to Participate in Upcoming Investor Conferences in March

Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis

PHILADELPHIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to CABA-201, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy, for the treatment of idiopathic inflammatory myopathies (IIM, or myositis). CABA-201 is in development as a potential treatment for autoimmune diseases driven by B cells. Four RESET™ (REstoring SElf-Tolerance) Phase 1/2 trials are advancing for the evaluation of CABA-201 across multiple autoimmune conditions, including the Phase 1/2 RESET-Myositis™ trial.

Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis

Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

PHILADELPHIA, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Wednesday, February 7, 2024 at 10:00 a.m. ET in New York, NY.

Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward

Initial data from the phase 1/2 study, using CABA-201 for the treatment of patients with systemic lupus erythematosus [both renal and non-renal], is expected in the 1st half of 2024. Initial data from the phase 1/2 study, using CABA-201 for the treatment of patients with myositis, is expected in the 1st half of 2024. Initial data from the phase 1/2 study, using CABA-201 for the treatment of patients with generalized myasthenia gravis, is expected in the 2nd half of 2024.

Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward

See News Rankings